Ucb Biopharma Srl

This study tested a drug called bimekizumab in 505 adults with moderate to severe hidradenitis suppurativa, a chronic skin condition causing painful lumps. The goal was to see if the drug reduces skin abscesses and inflammation better than a placebo. Results focus on symptom impr…

This study looked at the long-term safety of bimekizumab, a drug for moderate to severe plaque psoriasis, in 1353 adults. Participants who completed earlier studies received the drug and were monitored for side effects over time. The goal was to see how safe and tolerable the tre…

This study tested a new drug called bimekizumab against an existing drug, secukinumab, in 743 adults with moderate-to-severe plaque psoriasis. The main goal was to see which drug cleared more skin completely by week 16. Both drugs are given by injection and aim to control the dis…

This study tested a drug called bimekizumab in 509 adults with moderate to severe hidradenitis suppurativa, a chronic skin condition that causes painful lumps and tunnels under the skin. The goal was to see if the drug could reduce these lesions by at least 50% after 16 weeks com…

This study tested a drug called bimekizumab in 400 adults with active psoriatic arthritis who had not improved with standard treatments. The goal was to see if the drug could reduce joint pain and swelling better than a placebo. Results showed significant improvement in arthritis…

This study tested a drug called bimekizumab in 274 adults with a form of spinal arthritis that doesn't show up on X-rays (nonradiographic axial spondyloarthritis). The goal was to see if the drug could reduce pain, stiffness, and improve function better than a placebo. Participan…

This study tested an experimental oral medication, UCB0599, in 496 people with early-stage Parkinson's disease. Participants received either the drug or a placebo for 18 months. The goal was to see if UCB0599 could safely slow the worsening of Parkinson's symptoms, such as moveme…

This study tested an experimental drug called UCB0022 in 207 people with advanced Parkinson's disease. The goal was to see if adding UCB0022 to standard treatment (including levodopa) could reduce the daily hours when symptoms return, known as 'OFF' time. Participants were random…

This study involved 14 healthy adults to see if injecting zilucoplan with a prefilled syringe works the same as using an auto-injector. Researchers measured how much drug got into the blood and checked for side effects. The goal was to compare the two devices, not to treat any di…